• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促肾上腺皮质激素释放因子受体(CRFR)肽拮抗剂的结构要求:CRFR2β选择性抗 sauvagine-30 的研发

Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30.

作者信息

Rühmann A, Bonk I, Lin C R, Rosenfeld M G, Spiess J

机构信息

Department of Molecular Neuroendocrinology, Max Planck Institute for Experimental Medicine, Hermann-Rein-Strasse 3, D-37075 Göttingen, Germany.

出版信息

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15264-9. doi: 10.1073/pnas.95.26.15264.

DOI:10.1073/pnas.95.26.15264
PMID:9860957
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC28031/
Abstract

Different truncated and conformationally constrained analogs of corticotropin-releasing factor (CRF) were synthesized on the basis of the amino acid sequences of human/rat CRF (h/rCRF), ovine CRF (oCRF), rat urocortin (rUcn), or sauvagine (Svg) and tested for their ability to displace [125I-Tyr0]oCRF or [125I-Tyr0]Svg from membrane homogenates of human embryonic kidney (HEK) 293 cells stably transfected with cDNA coding for rat CRF receptor, type 1 (rCRFR1), or mouse CRF receptor, type 2beta (mCRFR2beta). Furthermore, the potency of CRF antagonists to inhibit oCRF- or Svg-stimulated cAMP production of transfected HEK 293 cells expressing either rCRFR1 (HEK-rCRFR1 cells) or mCRFR2beta (HEK-mCRFR2beta cells) was determined. In comparison with astressin, which exhibited a similar affinity to rCRFR1 (Kd = 5.7 +/- 1.6 nM) and mCRFR2beta (Kd = 4.0 +/- 2.3 nM), [DPhe11,His12]Svg(11-40), [DLeu11]Svg(11-40), [DPhe11]Svg(11-40), and Svg(11-40) bound, respectively, with a 110-, 80-, 68-, and 54-fold higher affinity to mCRFR2beta than to rCRFR1. The truncated analogs of rUcn displayed modest preference (2- to 7-fold) for binding to mCRFR2beta. In agreement with the results of these binding experiments, [DPhe11, His12]Svg(11-40), named antisauvagine-30, was the most potent and selective ligand to suppress agonist-induced adenylate cyclase activity in HEK cells expressing mCRFR2beta.

摘要

基于人/大鼠促肾上腺皮质激素释放因子(h/rCRF)、绵羊促肾上腺皮质激素释放因子(oCRF)、大鼠尿皮质素(rUcn)或蛙皮素(Svg)的氨基酸序列,合成了不同的截短型和构象受限类似物,并测试了它们从稳定转染了编码大鼠促肾上腺皮质激素释放因子受体1型(rCRFR1)或小鼠促肾上腺皮质激素释放因子受体2β型(mCRFR2β)的cDNA的人胚肾(HEK)293细胞膜匀浆中置换[125I-Tyr0]oCRF或[125I-Tyr0]Svg的能力。此外,还测定了促肾上腺皮质激素释放因子拮抗剂抑制表达rCRFR1(HEK-rCRFR1细胞)或mCRFR2β(HEK-mCRFR2β细胞)的转染HEK 293细胞中oCRF或Svg刺激的cAMP产生的效力。与对rCRFR1(Kd = 5.7 +/- 1.6 nM)和mCRFR2β(Kd = 4.0 +/- 2.3 nM)表现出相似亲和力的阿斯特辛相比,[DPhe11,His12]Svg(11-40)、[DLeu11]Svg(11-40)、[DPhe11]Svg(11-40)和Svg(11-40)与mCRFR2β的结合亲和力分别比对rCRFR1高110倍、80倍、68倍和54倍。rUcn的截短类似物对mCRFR2β的结合显示出适度的偏好(2至7倍)。与这些结合实验的结果一致,名为抗蛙皮素-30的[DPhe11, His12]Svg(11-40)是抑制表达mCRFR2β的HEK细胞中激动剂诱导的腺苷酸环化酶活性的最有效和选择性最强的配体。

相似文献

1
Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30.促肾上腺皮质激素释放因子受体(CRFR)肽拮抗剂的结构要求:CRFR2β选择性抗 sauvagine-30 的研发
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15264-9. doi: 10.1073/pnas.95.26.15264.
2
Development of a selective photoactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF2).
Eur J Biochem. 2002 Nov;269(21):5288-94. doi: 10.1046/j.1432-1033.2002.03246.x.
3
Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).新型促肾上腺皮质激素释放因子(CRF)的高亲和力光可活化拮抗剂:对1型CRF受体(CRFR1)的光亲和标记研究
Eur J Biochem. 2000 May;267(10):3017-24. doi: 10.1046/j.1432-1033.2000.01321.x.
4
Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.绵羊1型促肾上腺皮质激素释放因子受体(CRF1)及其羧基末端变体的结构与功能
Mol Cell Endocrinol. 1998 Sep 25;144(1-2):21-35. doi: 10.1016/s0303-7207(98)00157-9.
5
High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1.尿皮质素和促肾上腺皮质激素释放因子(CRF)的高亲和力结合,但促肾上腺皮质激素释放因子不与G蛋白解偶联的促肾上腺皮质激素释放因子受体1(CRFR1)结合。
Peptides. 1999 Nov;20(11):1311-9. doi: 10.1016/s0196-9781(99)00136-9.
6
125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.125I-酪氨酰蛙皮素:一种用于人促肾上腺皮质激素释放因子2α受体药理和生化研究的新型高亲和力放射性配体。
Mol Pharmacol. 1996 Sep;50(3):679-86.
7
A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.单个氨基酸作为促肾上腺皮质激素释放因子受体与结合蛋白之间的亲和力开关:对激动剂和拮抗剂设计的启示。
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11142-7. doi: 10.1073/pnas.211424998.
8
Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands.促肾上腺皮质激素释放因子(CRF)受体亚型对肽类配体N端截短的差异反应性。
Peptides. 2002 May;23(5):881-8. doi: 10.1016/s0196-9781(02)00014-1.
9
The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.高选择性促肾上腺皮质激素释放因子(CRF)(2)受体拮抗剂K41498与大鼠脑中的突触前CRF(2)受体结合。
Br J Pharmacol. 2002 Jul;136(6):896-904. doi: 10.1038/sj.bjp.0704783.
10
Design, synthesis and pharmacological characterization of new highly selective CRF(2) antagonists: development of 123I-K31440 as a potential SPECT ligand.
Peptides. 2002 Mar;23(3):453-60. doi: 10.1016/s0196-9781(01)00640-4.

引用本文的文献

1
Development and use of a high-throughput screen to identify novel modulators of the corticotropin releasing factor binding protein.开发和利用高通量筛选方法来鉴定新型促肾上腺皮质激素释放因子结合蛋白调节剂。
SLAS Discov. 2022 Dec;27(8):448-459. doi: 10.1016/j.slasd.2022.09.005. Epub 2022 Oct 7.
2
Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders.促肾上腺皮质素释放因子结合蛋白(CRF-BP)作为阿尔茨海默病和应激障碍的潜在新治疗靶点。
Transl Psychiatry. 2019 Oct 22;9(1):272. doi: 10.1038/s41398-019-0581-8.
3
Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction.促肾上腺皮质激素释放激素受体2会加剧慢性心脏功能障碍。
J Exp Med. 2017 Jul 3;214(7):1877-1888. doi: 10.1084/jem.20161924. Epub 2017 May 26.
4
Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.将厚皮美杜莎蛙皮素类似物表征为用于促肾上腺皮质激素释放因子受体研究的新型高亲和力放射性配体。
J Pharmacol Exp Ther. 2015 May;353(2):307-17. doi: 10.1124/jpet.114.222307. Epub 2015 Mar 3.
5
CRF2 Receptor Deficiency Eliminates the Long-Lasting Vulnerability of Motivational States Induced by Opiate Withdrawal.促肾上腺皮质激素释放因子2受体缺陷消除了阿片类药物戒断诱导的动机状态的长期易损性。
Neuropsychopharmacology. 2015 Jul;40(8):1990-2000. doi: 10.1038/npp.2015.49. Epub 2015 Feb 12.
6
Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance.促肾上腺皮质素释放因子肽拮抗剂:设计、表征及潜在临床相关性。
Front Neuroendocrinol. 2014 Apr;35(2):161-70. doi: 10.1016/j.yfrne.2013.10.006. Epub 2013 Nov 20.
7
Anxiolytic-like effects of antisauvagine-30 in mice are not mediated by CRF2 receptors.抗 Sauvagine-30 在小鼠体内产生的抗焦虑样作用不通过 CRF2 受体介导。
PLoS One. 2013 Aug 28;8(8):e63942. doi: 10.1371/journal.pone.0063942. eCollection 2013.
8
Nicotine stimulates secretion of corticosterone via both CRH and AVP receptors.尼古丁通过 CRH 和 AVP 受体刺激皮质酮的分泌。
J Neurochem. 2012 Mar;120(6):1108-16. doi: 10.1111/j.1471-4159.2011.07633.x. Epub 2012 Jan 23.
9
Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.促肾上腺皮质激素释放激素受体信号转导机制的研究进展。
Br J Pharmacol. 2012 May;166(1):85-97. doi: 10.1111/j.1476-5381.2011.01631.x.
10
Corticotropin releasing factor-induced CREB activation in striatal neurons occurs via a novel Gβγ signaling pathway.促肾上腺皮质释放因子诱导纹状体神经元中 CREB 的激活是通过一种新型的 Gβγ信号通路实现的。
PLoS One. 2011 Mar 23;6(3):e18114. doi: 10.1371/journal.pone.0018114.

本文引用的文献

1
Molecular Properties of the CRF Receptor.CRF 受体的分子特性。
Trends Endocrinol Metab. 1998 May-Jun;9(4):140-5. doi: 10.1016/s1043-2760(98)00037-x.
2
Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.使用新型放射性配体[3H] - 尿皮质素对促肾上腺皮质激素释放因子1(CRF1)和促肾上腺皮质激素释放因子2(CRF2)受体进行标记。
Neuropharmacology. 1997 Oct;36(10):1439-46. doi: 10.1016/s0028-3908(97)00098-1.
3
Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors.人促肾上腺皮质激素释放因子受体激动剂和拮抗剂结合域的定位
Mol Endocrinol. 1997 Dec;11(13):2048-53. doi: 10.1210/mend.11.13.0034.
4
The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist.CRF1受体介导促肾上腺皮质激素释放因子(CRF)在发育中大鼠脑内的兴奋性作用:使用新型、选择性、非肽类CRF受体拮抗剂的体内证据。
Brain Res. 1997 Oct 3;770(1-2):89-95. doi: 10.1016/s0006-8993(97)00759-2.
5
Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.具有i-(i + 3) 谷氨酸-赖氨酸桥的约束性促肾上腺皮质激素释放因子拮抗剂。
J Med Chem. 1997 Oct 24;40(22):3651-8. doi: 10.1021/jm970311t.
6
Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor.
J Neurochem. 1997 Oct;69(4):1640-9. doi: 10.1046/j.1471-4159.1997.69041640.x.
7
A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor.
Biochim Biophys Acta. 1997 May 30;1352(2):129-32. doi: 10.1016/s0167-4781(97)00047-x.
8
Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.一系列非肽类高亲和力人促肾上腺皮质激素释放因子1受体拮抗剂的设计与合成
J Med Chem. 1996 Oct 25;39(22):4358-60. doi: 10.1021/jm960149e.
9
A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity.一种非肽类促肾上腺皮质激素释放因子受体拮抗剂可减轻发热并表现出抗焦虑样活性。
Eur J Pharmacol. 1996 Aug 8;309(2):195-200. doi: 10.1016/0014-2999(96)00337-8.
10
Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling.用于特异性受体标记的促肾上腺皮质激素释放因子光活化类似物的合成与表征
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10609-13. doi: 10.1073/pnas.93.20.10609.